FDA Speeds Up Rare Kid Med with Magic Voucher System
Published Date: 1/21/2026
Notice
Summary
The FDA just approved RHAPSIDO (remibrutinib) using a special Rare Pediatric Disease Priority Review Voucher, speeding up its review because it treats a rare childhood illness. This helps companies get their important medicines to kids faster and encourages more rare disease research. The approval happened on September 30, 2025, and signals ongoing support for rare pediatric treatments.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
RHAPSIDO Approved for Rare Pediatric Use
The FDA approved RHAPSIDO (remibrutinib) on September 30, 2025, as a product that redeemed a Rare Pediatric Disease Priority Review Voucher. If your child has the rare pediatric condition this drug treats, this approval means an FDA-approved treatment is now available.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in